Beihai Kangcheng-B (01228) has fully initiated registration procedures and commercialization preparations for Golening in key markets in North Africa

According to the Zhitong Finance App, Beihai Kangcheng-B (01228) announced that the group has fully initiated registration procedures and commercialization preparations for Golening in key markets in North Africa, and preparations for the listing are progressing in an orderly manner. The North African market is impressive and continues to grow, and there is a large amount of unmet clinical demand. The Group took Gorening's overseas market to the North African market as the first step in the increasingly large-scale layout of the global Gaucher disease market.

According to reports, Gorenin was approved for marketing by the State Drug Administration of the People's Republic of China on May 15, 2025. It is the first locally developed long-term enzyme replacement therapy for young people aged 12 and above and adults with type I and III Gaucher disease. Gorening is the company's first self-developed enzyme replacement therapy, and the company holds exclusive global rights to develop and commercialize this product. As a bioinnovative drug, Gorenin can replace similar imported products, which is expected to reduce treatment costs, thereby improving treatment accessibility and long-term drug sustainability for patients with Gaucher disease around the world. In addition, the company is carrying out a registered clinical trial approved by the State Drug Administration to expand the application of Gorenin to children aged 2 and under 12.

The company believes that Gorening's overseas market to the North African market is an important milestone in the Group's layout and continuous expansion of the global Gaucher disease market. It is expected that it will not only improve the accessibility of treatment for patients with Gaucher disease in North Africa, but also enrich the Group's revenue structure and expand its profit base in the medium to long term, bringing long-term value to shareholders.